



The compilation of presentations is for educational purposes only. Copies of posters obtained through links are live the day of the presentation and per the meeting's guidelines, link to the conference website for obtaining the presentation. Copies of posters obtained through links are for personal use only and may not be reproduced without permission from ASCO® or the author of those posters. All copyrights protected by law. Solely for non-commercial use. © Pfizer Inc. All rights reserved.

In accordance with ASCO guidelines, ASCO presentations can be accessed on the ASCO Congress site.

Saturday, June 4

Poster Session: Gastrointestinal Cancer—Colorectal and Anal

Hall A8:00AM–11:00AM CDT

EncorafenibTPS3634

SEAMARK: Randomized phase 2 study of pembrolizumab + encorafenib + cetuximab versus pembrolizumab alone for first-line treatment of *BRAF* V600E-mutant microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC).
Kopetz S

[View Presentation](#)

Poster Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft

Hall A8:00AM–11:00AM CDT

Bosutinib7049

Bosutinib (BOS) in newly diagnosed chronic myeloid leukemia (CML): Gastrointestinal (GI), liver, effusion, and renal safety characterization in the BFORE trial.
Cortes JE

[View Presentation](#)

Poster Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Hall A8:00AM–11:00AM CDT

TTI-622TPS7595

TTI-622-01: A phase 1a/1b dose-escalation and expansion trial of TTI-622 in patients with advanced hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL).
Patel K

[View Presentation](#)

Poster Session: Hematologic Malignancies—Plasma Cell Dyscrasia

Hall A8:00AM–11:00AM CDT

ElranatamabTPS8068

MagnetisMM-9: An open-label, multicenter, non-randomized phase 1/2 study of elranatamab in patients with relapsed/refractory multiple myeloma.
Fonseca R

[View Presentation](#)**TTI-622**TPS8071

TTI-622-01: A phase 1a/1b dose-escalation and expansion trial of TTI-622 in patients with advanced hematologic malignancies, including multiple myeloma.
Patel K

[View Presentation](#)**Elranatamab**TPS8074

MagnetisMM-5: An open-label, multicenter, randomized phase 3 study of elranatamab as monotherapy and in combination with daratumumab in patients with relapsed/refractory multiple myeloma.
Grosicki S

[View Presentation](#)

Poster Session: Genitourinary Cancer—Kidney and Bladder

Hall A1:15PM–4:15PM CDT

Avelumab4559

Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1L chemotherapy.
Pérez-Valderrama B
Presentation is supported by Merck-EMD and Pfizer Alliance.

[View Presentation](#)**Avelumab**4560

Long-term outcomes in patients with advanced urothelial carcinoma (UC) who received avelumab first-line (1L) maintenance with or without second-line (2L) treatment: Exploratory analyses from JAVELIN Bladder 100.
Bellmunt J
Presentation is supported by Merck-EMD and Pfizer Alliance.

[View Presentation](#)**Avelumab**4595

Evaluating oncologists' practice patterns and decision-making in locally advanced or metastatic urothelial carcinoma (la/mUC): The U.S. physician PARADIGM study (Part 2).
Liu F
Presentation is supported by Merck-EMD and Pfizer Alliance.

[View Presentation](#)**Sasanlimab**TPS4614

A phase 3 study of the subcutaneous programmed cell death protein 1 inhibitor sasanlimab as single agent for patients with bacillus Calmette-Guérin unresponsive high-risk non-muscle invasive bladder cancer: CREST Study Cohort B.
Shore N

[View Presentation](#)

Oral Abstract Session: Breast Cancer—Metastatic

Hall D11:15PM–4:15PM CDT (Session)

2:15PM–2:26PM CDT (Presentation)

PalbociclibLBA1003

Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2– ABC): Analyses from PALOMA-2.
Finn RS

[View Presentation](#)

Poster Discussion Session: Hematologic Malignancies—Plasma Cell Dyscrasia

E4514:30PM–6:00PM CDT

Elranatamab8014

Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: Updated results from MagnetisMM-1.
Jakubowiak A

[View Presentation](#)

Sunday, June 5

Poster Session: Sarcoma

Hall A8:00AM–11:00AM CDT

PalbociclibTPS11583

Phase 2 study to evaluate palbociclib in combination with irinotecan and temozolomide in pediatric patients with recurrent or refractory Ewing sarcoma.
Laetsch TW

[View Presentation](#)**TTI-621**TPS11593

TTI-621-03: A phase I/II study of TTI-621 in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma (LMS).
Chawla SP

[View Presentation](#)

Oral Abstract Session: Hematologic Malignancies—Plasma Cell Dyscrasia

S4068:00AM - 11:00AM CDT (Session)

10:00AM - 10:11AM CDT (Presentation)

Elranatamab8006

Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM).
Lesokhin AM

[View Presentation](#)

Monday, June 6

Poster Session: Breast Cancer—Metastatic

Hall A8:00AM–11:00AM CDT

Palbociclib1069

A novel analysis of data from the PALOMA-3 trial confirms the efficacy of palbociclib and provides an option for efficacy assessments that could accelerate drug approvals.
Yeh C

[View Presentation](#)**ARV-471 and Palbociclib**TPS1120

ARV-471, an estrogen receptor (ER) PROTAC degrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2–negative (HER2–) breast cancer: Phase 1b cohort (part C) of a phase 1/2 study.
Hamilton EP
Presentation is supported by Pfizer and ARVINAS.

[View Presentation](#)

Poster Session: Lung Cancer—Non-Small Cell Metastatic

Hall A8:00AM–11:00AM CDT

Lorlatinib9069

Progression-free survival with subsequent anticancer therapies from a phase 3 trial of lorlatinib in treatment-naïve patients (pts) with *ALK*+ advanced non-small cell lung cancer (NSCLC).
Solomon BJ

[View Presentation](#)**Lorlatinib**9070

Phase 3 trial of lorlatinib in treatment-naïve patients (Pts) with *ALK*-positive advanced non-small cell lung cancer (NSCLC): Comprehensive plasma and tumor genomic analyses.
Bearz A

[View Presentation](#)

Poster Session: Genitourinary Cancer—Prostate, Testicular, and Penile

Hall A1:15PM–4:15PM CDT

Enzalutamide5022

The association of germline *HSD3B1* genotype with outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without enzalutamide (ENZA) [ARCHES].
Sharifi N
Presentation is supported by Astellas Pharma Inc. and Pfizer Alliance.

[View Presentation](#)**Enzalutamide**5065

Reasons for oncologist and urologist treatment choice in metastatic castration-sensitive prostate cancer (mCSPC): A physician survey linked to patient chart reviews in the United States.
Freedland SJ

[View Presentation](#)**Enzalutamide**5069

Clinical outcomes and safety of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) in patients aged < 75 and ≥ 75 years: ARCHES post hoc analysis.
Szmulewicz RZ
Presentation is supported by Astellas Pharma Inc. and Pfizer Alliance.

[View Presentation](#)**Enzalutamide**5072

Radiographic progression in the absence of prostate-specific antigen (PSA) progression in patients with metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analysis of ARCHES.
Armstrong AJ
Presentation is supported by Astellas Pharma Inc. and Pfizer Alliance.

[View Presentation](#)**Relugolix**5073

Efficacy and safety of relugolix in men with advanced prostate cancer based on baseline body mass index (BMI): A subgroup analysis from the randomized, phase 3 HERO study versus leuprolide (LEU).
Saad F
Presentation is supported by Myovant and Pfizer Alliance.

[View Presentation](#)**Enzalutamide**5074

Prevalence of DNA damage repair (DDR) alterations in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving enzalutamide (ENZA) or placebo (PBO) plus androgen deprivation therapy (ADT): ARCHES post hoc analysis.
Azad A
Presentation is supported by Astellas Pharma Inc. and Pfizer Alliance.

[View Presentation](#)**Talazoparib**TPS5096

TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo plus ENZA in patients with DDR gene-mutated, metastatic castration-sensitive prostate cancer (mCSPC).
Agarwal N

[View Presentation](#)

Publication Only

Enzalutamidee18757

Patient preferences for treatment and outcomes in hormone-sensitive prostate cancer (HSPC).
George DJ
Presentation is supported by Astellas Pharma Inc. and Pfizer Alliance.

[View Presentation](#)**Biosimilar**e18836

Projected impact of oncology biosimilar substitution from the perspective of provider risk in value-based oncology payment models.
Yang J

[View Presentation](#)**Inotuzumab Ozogamicin**e19009

Characteristics of Medicare patients with relapsed/refractory acute lymphoblastic leukemia initiating treatment with inotuzumab ozogamicin, blinatumomab, or other agents.
Russell-Smith TA

[View Presentation](#)**Bosutinib**e19055

Efficacy and safety of bosutinib in later-line patients (pts) with chronic myeloid leukemia (CML): A sub-analysis from the phase 4 BYOND trial.
Gambacorti-Passerini C

[View Presentation](#)**Avelumab**e21528

Safety and effectiveness of avelumab in patients with curatively unresectable merkel cell carcinoma (MCC) in a real-world setting: A post-marketing surveillance in Japan.
Uhara H
Presentation is supported by Merck-EMD and Pfizer Alliance.

[View Presentation](#)